Clinical Trial: A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06855823) titled 'A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL' on Jan. 16.

Brief Summary: This is a phase I/II clinical trial to evaluate the efficacy and safety of Golidocitinib combined with Pomalidomide for relapsed/refractory peripheral T-cell lymphoma.

Study Start Date: Jan. 14

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Intervention: DRUG: Golicitinib combined with Pomadomide

golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd

Recruitment Status: RECRUITING

Sponsor: Sun Yat-sen University

Information provided by (Responsible Party): Li Zhiming, Sun Yat-se...